The main differentiating factor for Abdi Ibrahim among Turkish companies is our willingness to invest in, and collaborate with, international players
In Conversation
We are close to having the technological capacity to develop all types of biosimilar products, even some novel ones
The medical infrastructure in Turkey is substantial with many large hospitals. However, for clinical trials, we need more dedicated places to conduct clinical trials, an institutional…
The Turkish authorities continue to be content with the current [pricing] system because it has been sustained until today. The question the industry is asking itself…
The objective [for Turkey] now should be to implement policies in areas like rare diseases so that we can expedite access to innovative medicines for diseases…
The importance and urgency of developing a vaccine during the COVID-19 pandemic is obvious
Turkey has a unique value proposition, bringing European perfection at an affordable cost, and Novartis has made investments to make the country a quality export launchpad
We are on board with the idea of including Turkey in more clinical trials. Today, the country is very involved with Bayer's innovative products from the…
Positioning Turkey as a regional hub for the Menarini Group is a sign of senior management’s great confidence in the country and its people, and a…
We have set some goals not only as an industry but as a country: increase the production of high-value products not only in pharma but across…
It is important to look at healthcare as an investment, rather than a burden on the public budget: an investment in the population, their health and…
[R&D] is the gateway to successful production and competition in the marketplace. Without R&D, DEVA would not be where it is today
